首页 > 最新文献

Clinical Microbiology and Infection最新文献

英文 中文
Clinical microbiology and infection supports early-career researchers. 临床微生物学和感染支持早期职业研究人员。
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-09 DOI: 10.1016/j.cmi.2026.01.004
J Friedman, L Leibovici
{"title":"Clinical microbiology and infection supports early-career researchers.","authors":"J Friedman, L Leibovici","doi":"10.1016/j.cmi.2026.01.004","DOIUrl":"10.1016/j.cmi.2026.01.004","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The diagnostic accuracy of procalcitonin for community-acquired bacteraemia: an updated systematic review and meta-analysis. 降钙素原对社区获得性菌血症的诊断准确性:一项最新的系统综述和荟萃分析。
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-08 DOI: 10.1016/j.cmi.2025.12.029
Anna G Kaal, Margot Nieberg, Koen Stegmeijer, Ewout W Steyerberg, Cees van Nieuwkoop

Background: Procalcitonin is known to have moderate diagnostic accuracy for bacteraemia. A 2014 meta-analysis showed 76% sensitivity for a 0.50-ng/mL threshold. Lower thresholds might improve sensitivity.

Objectives: To determine the diagnostic accuracy of procalcitonin for community-acquired bacteraemia by conducting a systematic review and meta-analysis, focusing on the ability to exclude bacteraemia.

Methods: Data sources: We searched PUBMED, EMBASE and Web of Science from 1 January 2014 to 20 May 2025.

Study eligibility criteria and participants: Articles studying diagnostic accuracy of procalcitonin for community-acquired bacteraemia in adults.

Test and reference standard: Procalcitonin was compared with blood culture results.

Assessment of risk of bias: Risk of bias was assessed using the QUADAS-2 tool.

Methods of data synthesis: We pooled sensitivity/specificity with a bivariate random-effects model and created a summary receiver-operating curve. The main analysis focused on studies reporting on a procalcitonin threshold of 0.10 ng/mL. In addition, we analysed results for all studies, studies with a 0.25-ng/mL and studies with a 0.50-ng/mL threshold.

Results: We included 40 of 5450 identified articles, reflecting 192 529 patients of whom 31 480 (16%) had bacteraemia. Of 40 studies, 32 had high risk of bias. The pooled sensitivity for a 0.10-ng/mL threshold was 93% (95% CI: 85-97%) with a specificity of 36% (95% CI: 26-47%). The area under the summary receiver-operating curve for all studies was 0.80 (95% CI: 0.76-0.83%; prediction interval 0.57-0.91).

Discussion: A low cut-off value of procalcitonin can be useful to exclude community-acquired bacteraemia, depending on what the treating clinician considers to be an acceptable trade-off between sensitivity and specificity. Procalcitonin may require combination with clinical characteristics for accurate assessment of the risk of bacteraemia and safely reducing unnecessary blood cultures.

背景:已知降钙素原对菌血症有中等的诊断准确性。2014年的一项荟萃分析显示,对0.50 ng/mL阈值的敏感性为76%。降低阈值可能会提高灵敏度。目的:通过进行系统回顾和荟萃分析,确定降钙素原对社区获得性菌血症的诊断准确性,重点是排除菌血症的能力。方法数据来源:检索PUBMED、EMBASE和Web of Science,检索时间为2014年1月1日至2025年5月20日。研究资格标准和参与者:研究降钙素原对成人社区获得性菌血症诊断准确性的文章。试验与参考标准:将降钙素原与血培养结果进行比较。偏倚风险评估:使用QUADAS-2工具评估偏倚风险。数据综合方法:我们将敏感性/特异性与双变量随机效应模型合并,并创建了汇总的接受者-操作(sROC)曲线。主要分析集中在报告降钙素原阈值为0.10 ng/mL的研究。此外,我们分析了所有研究的结果,0.25 ng/mL和0.50 ng/mL阈值的研究。结果:我们纳入了5450篇鉴定文章中的40篇,反映了192.529例患者,其中31.480例(16%)有菌血症。40项研究中有32项存在高偏倚风险。0.10 ng/mL阈值的总敏感性为93% (95% CI: 85% - 97%),特异性为36% (95% CI: 26% - 47%)。所有研究的sROC曲线下面积为0.80 (95% CI: 0.76 ~ 0.83),预测区间(PI) 0.57 ~ 0.91。讨论:PCT的低临界值可用于排除社区获得性菌血症,这取决于治疗临床医生认为在敏感性和特异性之间可以接受的权衡。降钙素原可能需要与临床特征相结合,以准确评估菌血症的风险,并安全减少不必要的血培养。
{"title":"The diagnostic accuracy of procalcitonin for community-acquired bacteraemia: an updated systematic review and meta-analysis.","authors":"Anna G Kaal, Margot Nieberg, Koen Stegmeijer, Ewout W Steyerberg, Cees van Nieuwkoop","doi":"10.1016/j.cmi.2025.12.029","DOIUrl":"10.1016/j.cmi.2025.12.029","url":null,"abstract":"<p><strong>Background: </strong>Procalcitonin is known to have moderate diagnostic accuracy for bacteraemia. A 2014 meta-analysis showed 76% sensitivity for a 0.50-ng/mL threshold. Lower thresholds might improve sensitivity.</p><p><strong>Objectives: </strong>To determine the diagnostic accuracy of procalcitonin for community-acquired bacteraemia by conducting a systematic review and meta-analysis, focusing on the ability to exclude bacteraemia.</p><p><strong>Methods: </strong>Data sources: We searched PUBMED, EMBASE and Web of Science from 1 January 2014 to 20 May 2025.</p><p><strong>Study eligibility criteria and participants: </strong>Articles studying diagnostic accuracy of procalcitonin for community-acquired bacteraemia in adults.</p><p><strong>Test and reference standard: </strong>Procalcitonin was compared with blood culture results.</p><p><strong>Assessment of risk of bias: </strong>Risk of bias was assessed using the QUADAS-2 tool.</p><p><strong>Methods of data synthesis: </strong>We pooled sensitivity/specificity with a bivariate random-effects model and created a summary receiver-operating curve. The main analysis focused on studies reporting on a procalcitonin threshold of 0.10 ng/mL. In addition, we analysed results for all studies, studies with a 0.25-ng/mL and studies with a 0.50-ng/mL threshold.</p><p><strong>Results: </strong>We included 40 of 5450 identified articles, reflecting 192 529 patients of whom 31 480 (16%) had bacteraemia. Of 40 studies, 32 had high risk of bias. The pooled sensitivity for a 0.10-ng/mL threshold was 93% (95% CI: 85-97%) with a specificity of 36% (95% CI: 26-47%). The area under the summary receiver-operating curve for all studies was 0.80 (95% CI: 0.76-0.83%; prediction interval 0.57-0.91).</p><p><strong>Discussion: </strong>A low cut-off value of procalcitonin can be useful to exclude community-acquired bacteraemia, depending on what the treating clinician considers to be an acceptable trade-off between sensitivity and specificity. Procalcitonin may require combination with clinical characteristics for accurate assessment of the risk of bacteraemia and safely reducing unnecessary blood cultures.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of viridans streptococci and anaerobic bacteria of the oral cavity in paediatric parapneumonic pleural effusions/empyema-a nationwide hospital-based surveillance study. 青绿链球菌和口腔厌氧菌在小儿肺炎旁胸腔积液/脓气肿中的作用——一项全国性医院监测研究
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-08 DOI: 10.1016/j.cmi.2025.12.025
Philipp Reuter-Weissenberger, Johannes Liese, Carsten Bauer, Michael S Urschitz, Christoph Schoen, Johannes Forster, Andrea Streng

Objectives: Parapneumonic pleural effusions/empyema (PPE/PE) are serious complications of community-acquired pneumonia in children. Although Streptococcus pneumoniae and Streptococcus pyogenes are established major pathogens, the clinical relevance of oral cavity bacteria (viridans streptococci and/or anaerobic bacteria [VS/AA]) in paediatric PPE/PE is largely unclear.

Methods: A nationwide hospital-based surveillance study in Germany recorded children aged <18 years with PPE/PE from October 2010 to June 2023, with bacteria detected from pleural fluid and/or blood. We compared clinical characteristics of patients with VS/AA-associated PPE/PE with those of patients with S. pneumoniae- or S. pyogenes-associated PPE/PE (reference group) using multivariable regression analysis, with results presented as regression coefficient (RC) or OR with 95% CI, respectively.

Results: Among 1242 children with any identified PPE/PE-associated pathogen, 115 (9.3%) presented with VS/AA and 818 (65.9%) with S. pneumoniae or S. pyogenes. Compared with the reference group, children with VS/AA-associated PPE/PE were older (median [interquartile range]: 11.4 [4.9-14.9] vs. 3.6 [2.2-5.7] years, p < 0.001) and had more underlying diseases (46.1% [53/115] vs. 22.2% [182/818], p < 0.001), mainly complex neurological comorbidities (25.2% [29/115]). In multivariable analyses, VS/AA vs. reference patients showed a similar duration of hospital stay (median [interquartile range]: 20 days [15-28] vs. 18 days [14-25], p 0.467), and a similar proportion required treatment at a paediatric intensive care unit (80.0% [92/115] vs. 81.5% [667/818], p 0.992). VS/AA patients had a longer time from symptom onset to hospital admission or to discharge (by 4.1 days [RC, 95% CI 2.5-5.7, p < 0.001] and by 5.2 days [RC, 95% CI 2.1-8.3, p 0.001], respectively) and needed longer paediatric intensive care unit treatment (by 3.1 days, [RC, 95%CI 0.4-5.9, p 0.025]). They showed more frequent pulmonary complications, especially atelectasis (65.2% [75/115] vs. 50.6% [414/818]; OR 1.9, 95% CI 1.2-3.0, p 0.006) and pulmonary abscess (27.8% [32/115] vs. 19.8% [162/818]; OR 1.7, 95% CI 1.0-2.8, p 0.040). They were more likely to develop sequelae (41.6% [47/115] vs. 21.3% [173/818]; OR 2.3, 95% CI 1.5-3.7, p < 0.001) but less likely to develop sepsis/systemic inflammatory response syndrome (8.7% [10/115] vs. 18.1% [148/818]; OR 0.4, 95% CI 0.2-0.7, p 0.004).

Conclusions: VS/AA-associated PPE/PE particularly affected older children and those with complex comorbidities. In such patients, it would therefore be advisable to include anaerobic coverage in empirical antibiotic treatment, and distinct clinical features should be considered in therapeutic management.

目的:肺炎旁胸腔积液/脓胸(PPE/PE)是儿童社区获得性肺炎的严重并发症。虽然肺炎链球菌和化脓性链球菌是公认的主要病原体,但口腔细菌(翠绿链球菌、厌氧菌;VS/AA)在儿科PPE/PE中的临床相关性在很大程度上尚不清楚。结果:在1242名已确诊PPE/ pe相关病原体的儿童中,115名(9.3%)表现为VS/AA, 818名(65.9%)表现为肺炎链球菌或化脓性链球菌。与对照组相比,VS/ aa相关PPE/PE患儿年龄较大(中位[IQR]: 11.4 [4.9-14.9] VS . 3.6[2.2-5.7]岁)。结论:VS/ aa相关PPE/PE特别影响年龄较大的患儿和有复杂合共病的患儿。因此,对于此类患者,建议在经验性抗生素治疗中纳入厌氧覆盖,并在治疗管理中考虑不同的临床特征。
{"title":"The role of viridans streptococci and anaerobic bacteria of the oral cavity in paediatric parapneumonic pleural effusions/empyema-a nationwide hospital-based surveillance study.","authors":"Philipp Reuter-Weissenberger, Johannes Liese, Carsten Bauer, Michael S Urschitz, Christoph Schoen, Johannes Forster, Andrea Streng","doi":"10.1016/j.cmi.2025.12.025","DOIUrl":"10.1016/j.cmi.2025.12.025","url":null,"abstract":"<p><strong>Objectives: </strong>Parapneumonic pleural effusions/empyema (PPE/PE) are serious complications of community-acquired pneumonia in children. Although Streptococcus pneumoniae and Streptococcus pyogenes are established major pathogens, the clinical relevance of oral cavity bacteria (viridans streptococci and/or anaerobic bacteria [VS/AA]) in paediatric PPE/PE is largely unclear.</p><p><strong>Methods: </strong>A nationwide hospital-based surveillance study in Germany recorded children aged <18 years with PPE/PE from October 2010 to June 2023, with bacteria detected from pleural fluid and/or blood. We compared clinical characteristics of patients with VS/AA-associated PPE/PE with those of patients with S. pneumoniae- or S. pyogenes-associated PPE/PE (reference group) using multivariable regression analysis, with results presented as regression coefficient (RC) or OR with 95% CI, respectively.</p><p><strong>Results: </strong>Among 1242 children with any identified PPE/PE-associated pathogen, 115 (9.3%) presented with VS/AA and 818 (65.9%) with S. pneumoniae or S. pyogenes. Compared with the reference group, children with VS/AA-associated PPE/PE were older (median [interquartile range]: 11.4 [4.9-14.9] vs. 3.6 [2.2-5.7] years, p < 0.001) and had more underlying diseases (46.1% [53/115] vs. 22.2% [182/818], p < 0.001), mainly complex neurological comorbidities (25.2% [29/115]). In multivariable analyses, VS/AA vs. reference patients showed a similar duration of hospital stay (median [interquartile range]: 20 days [15-28] vs. 18 days [14-25], p 0.467), and a similar proportion required treatment at a paediatric intensive care unit (80.0% [92/115] vs. 81.5% [667/818], p 0.992). VS/AA patients had a longer time from symptom onset to hospital admission or to discharge (by 4.1 days [RC, 95% CI 2.5-5.7, p < 0.001] and by 5.2 days [RC, 95% CI 2.1-8.3, p 0.001], respectively) and needed longer paediatric intensive care unit treatment (by 3.1 days, [RC, 95%CI 0.4-5.9, p 0.025]). They showed more frequent pulmonary complications, especially atelectasis (65.2% [75/115] vs. 50.6% [414/818]; OR 1.9, 95% CI 1.2-3.0, p 0.006) and pulmonary abscess (27.8% [32/115] vs. 19.8% [162/818]; OR 1.7, 95% CI 1.0-2.8, p 0.040). They were more likely to develop sequelae (41.6% [47/115] vs. 21.3% [173/818]; OR 2.3, 95% CI 1.5-3.7, p < 0.001) but less likely to develop sepsis/systemic inflammatory response syndrome (8.7% [10/115] vs. 18.1% [148/818]; OR 0.4, 95% CI 0.2-0.7, p 0.004).</p><p><strong>Conclusions: </strong>VS/AA-associated PPE/PE particularly affected older children and those with complex comorbidities. In such patients, it would therefore be advisable to include anaerobic coverage in empirical antibiotic treatment, and distinct clinical features should be considered in therapeutic management.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The recent introduction of mosaic mtr-carrying Neisseria gonorrhoeae lineages boosts local transmission. 最近引入的携带镶嵌结核的淋病奈瑟菌谱系促进了当地传播。
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-07 DOI: 10.1016/j.cmi.2025.12.026
Andrea Sánchez-Serrano, Carlos Francés-Cuesta, Nuria Jiménez-Hernández, Lidia Ruiz-Roldán, Javier Colomina-Rodríguez, Devi Carolina Salas-Olortegui, Maria Jesús Castaño-Aroca, José Miguel Sahuquillo-Arce, Araceli Molina de Diego, José Luis López-Hontangas, José Luis Ramos Martí, Olalla Martínez-Macias, Nieves Orta Mira, Inmaculada Vidal Català, Victoria Dominguez-Márquez, Silvia Madrid Camacho, José Miguel Nogueira-Coíto, Cori Gázquez Gómez, Victoria Ortiz De La Tabla Ducasse, Oihana Sabalza-Baztán, María Gil-Fortuño, Óscar Pérez Olaso, Noelia Hernández Pérez, Mercedes Roig Cardells, Fernando González-Candelas, Leonor Sánchez-Busó

Objectives: Gonorrhoea, caused by Neisseria gonorrhoeae, is a significant public health challenge due to the rising incidence of antimicrobial resistant (AMR) strains. The Valencian Region, one of the top tourist destinations in Eastern Spain, has witnessed an increase of over 200% in the number of cases in recent years. Here, we aimed to investigate the impact of imported AMR lineages in shaping the local gonococcal population and generating sustained transmission events.

Methods: We analysed 1647 N. gonorrhoeae isolates collected in the Valencian Region between 2012 and 2024 with accompanying phenotypic antimicrobial susceptibility and epidemiological data. Genomic data was obtained through high-throughput sequencing and combined with 5894 genomes from national and international isolates. From these, information on typing and genetic AMR determinants was derived. Phylogenomic and statistical inference were used to investigate the local dynamics of this pathogen.

Results: Results revealed high levels of AMR, including 63.6% (n = 449/706) ciprofloxacin resistance, 17.7% (n = 195/1102) azithromycin resistance, and 8.4% (n = 66/783) reduced susceptibility or resistance to ceftriaxone. The two main circulating lineages were NG-STAR CC1615 and CC63, carrying 55.0% (n = 121/220) and 26.5% (n = 45/170) isolates with a mosaic mtr (mosaic mtrD and mtrR promoter), respectively. Phylodynamic analyses identified multiple introductions of AMR lineages into the region leading to sustained transmissions since the 1990s. These lineages significantly carried more isolates with mtr mosaics (OR = 4.17 [3.27-5.34]; p 1.26E-33) and phenotypic resistance to azithromycin (OR = 2.22 [1.60-3.06]; p 1.14E-06), among other antimicrobials.

Conclusions: This study highlights the dynamic evolution and dissemination of AMR N. gonorrhoeae at the local level, highlighting the role of international mobility, sexual networks, and antibiotic usage in shaping resistance patterns. Enhanced genomic surveillance, with special monitoring of mosaic mtr-carrying lineages, together with targeted public health interventions, will be key to curb local and regional spread of resistant gonococcal strains.

目的:淋病是由淋病奈瑟菌引起的,由于抗微生物药物耐药性(AMR)菌株的发病率上升,淋病是一个重大的公共卫生挑战。巴伦西亚地区是西班牙东部最热门的旅游目的地之一,近年来病例数量增加了200%以上。在这里,我们的目的是调查进口AMR谱系在塑造当地淋球菌种群和产生持续传播事件方面的影响。方法:分析2012-2024年在巴伦西亚地区采集的1647株淋病奈瑟菌分离株的表型药敏和流行病学资料。基因组数据通过高通量测序获得,并与国内和国际分离株的5894个基因组相结合。从这些,信息分型和遗传AMR决定因素推导。系统基因组学和统计学推断用于调查该病原体的局部动态。结果:AMR较高,其中环丙沙星耐药63.6% (n=449/706),阿奇霉素耐药17.7% (n=195/1102),头孢曲松药敏或耐药降低8.4% (n=66/783)。两个主要的循环系为NG-STAR CC1615和CC63,分别携带55.0% (n=121/220)和26.5% (n=45/170)具有马赛克mtr(马赛克mtrD和mtrR启动子)的分离株。系统动力学分析发现,自20世纪90年代以来,该地区多次引入AMR谱系,导致持续传播。在这些谱系中,具有mtr嵌合(OR=4.17 [3.27-5.34], p值=1.26E-33)和阿奇霉素表型耐药(OR=2.22 [1.60-3.06], p值=1.14E-06)的分离株显著增加。结论:本研究强调了AMR淋病奈瑟菌在地方层面的动态演变和传播,强调了国际流动、性网络和抗生素使用在形成耐药性模式中的作用。加强基因组监测,特别监测镶嵌型结核分枝杆菌携带谱系,加上有针对性的公共卫生干预措施,将是遏制耐药淋球菌菌株在当地和区域传播的关键。
{"title":"The recent introduction of mosaic mtr-carrying Neisseria gonorrhoeae lineages boosts local transmission.","authors":"Andrea Sánchez-Serrano, Carlos Francés-Cuesta, Nuria Jiménez-Hernández, Lidia Ruiz-Roldán, Javier Colomina-Rodríguez, Devi Carolina Salas-Olortegui, Maria Jesús Castaño-Aroca, José Miguel Sahuquillo-Arce, Araceli Molina de Diego, José Luis López-Hontangas, José Luis Ramos Martí, Olalla Martínez-Macias, Nieves Orta Mira, Inmaculada Vidal Català, Victoria Dominguez-Márquez, Silvia Madrid Camacho, José Miguel Nogueira-Coíto, Cori Gázquez Gómez, Victoria Ortiz De La Tabla Ducasse, Oihana Sabalza-Baztán, María Gil-Fortuño, Óscar Pérez Olaso, Noelia Hernández Pérez, Mercedes Roig Cardells, Fernando González-Candelas, Leonor Sánchez-Busó","doi":"10.1016/j.cmi.2025.12.026","DOIUrl":"10.1016/j.cmi.2025.12.026","url":null,"abstract":"<p><strong>Objectives: </strong>Gonorrhoea, caused by Neisseria gonorrhoeae, is a significant public health challenge due to the rising incidence of antimicrobial resistant (AMR) strains. The Valencian Region, one of the top tourist destinations in Eastern Spain, has witnessed an increase of over 200% in the number of cases in recent years. Here, we aimed to investigate the impact of imported AMR lineages in shaping the local gonococcal population and generating sustained transmission events.</p><p><strong>Methods: </strong>We analysed 1647 N. gonorrhoeae isolates collected in the Valencian Region between 2012 and 2024 with accompanying phenotypic antimicrobial susceptibility and epidemiological data. Genomic data was obtained through high-throughput sequencing and combined with 5894 genomes from national and international isolates. From these, information on typing and genetic AMR determinants was derived. Phylogenomic and statistical inference were used to investigate the local dynamics of this pathogen.</p><p><strong>Results: </strong>Results revealed high levels of AMR, including 63.6% (n = 449/706) ciprofloxacin resistance, 17.7% (n = 195/1102) azithromycin resistance, and 8.4% (n = 66/783) reduced susceptibility or resistance to ceftriaxone. The two main circulating lineages were NG-STAR CC1615 and CC63, carrying 55.0% (n = 121/220) and 26.5% (n = 45/170) isolates with a mosaic mtr (mosaic mtrD and mtrR promoter), respectively. Phylodynamic analyses identified multiple introductions of AMR lineages into the region leading to sustained transmissions since the 1990s. These lineages significantly carried more isolates with mtr mosaics (OR = 4.17 [3.27-5.34]; p 1.26E-33) and phenotypic resistance to azithromycin (OR = 2.22 [1.60-3.06]; p 1.14E-06), among other antimicrobials.</p><p><strong>Conclusions: </strong>This study highlights the dynamic evolution and dissemination of AMR N. gonorrhoeae at the local level, highlighting the role of international mobility, sexual networks, and antibiotic usage in shaping resistance patterns. Enhanced genomic surveillance, with special monitoring of mosaic mtr-carrying lineages, together with targeted public health interventions, will be key to curb local and regional spread of resistant gonococcal strains.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of resistance to newer drugs against gram negative bacteria in enterobacterales. 肠杆菌中革兰氏阴性菌对新药的耐药性机制。
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-07 DOI: 10.1016/j.cmi.2025.12.027
Mercedes Delgado-Valverde, Patricia Perez-Palacios, Lorena López-Cerero

Background: The emergence of multidrug-resistant Gram-negative bacteria poses a significant threat to global health. This has prompted the development of novel antimicrobials and combinations with β-lactamase inhibitors.

Objectives: This review aims to shed light on the resistance mechanisms associated with new drugs against Enterobacterales.

Sources: We searched PubMed relevant English literature in up to 30 June 2025, as well as including articles known to the authors. We analysed Enterobacterales resistance mechanisms for diazabicyclooctanes, bicyclic boronates, cefepime/enmetazobactam, cefiderocol, and eravacycline.

Content: The review summarises the main mechanisms of resistance to recently introduced ß-lactamase inhibitor families, including diazabicyclooctanes and bicyclic boronates, as well as other novel combinations or antimicrobials, such as cefiderocol and eravacycline.

Implications: Understanding how microorganisms develop resistance to new antimicrobials or combinations with inhibitors is essential for redesigning treatment strategies and for the design of future antibiotics.

背景:耐多药革兰氏阴性菌的出现对全球健康构成重大威胁。这促使了新型抗菌剂和ß-内酰胺酶抑制剂联合的发展。目的:本综述旨在揭示新药物对肠杆菌的耐药机制。来源:我们检索了截至2025年6月30日的PubMed相关英文文献,包括作者已知的文章。我们分析了肠杆菌对重氮环辛烷(DBOs)、双环硼酸盐、头孢吡肟/恩美他唑巴坦、头孢地罗和依瓦环素的耐药机制。内容:综述了最近引入的ß-内酰胺酶抑制剂家族的主要耐药机制,包括DBOs和双环硼酸盐,以及其他新的组合或抗菌素,如头孢地罗和依瓦环素。意义:了解微生物如何对新的抗菌素或抑制剂组合产生耐药性,对于重新设计治疗策略和设计未来的抗生素至关重要。
{"title":"Mechanisms of resistance to newer drugs against gram negative bacteria in enterobacterales.","authors":"Mercedes Delgado-Valverde, Patricia Perez-Palacios, Lorena López-Cerero","doi":"10.1016/j.cmi.2025.12.027","DOIUrl":"10.1016/j.cmi.2025.12.027","url":null,"abstract":"<p><strong>Background: </strong>The emergence of multidrug-resistant Gram-negative bacteria poses a significant threat to global health. This has prompted the development of novel antimicrobials and combinations with β-lactamase inhibitors.</p><p><strong>Objectives: </strong>This review aims to shed light on the resistance mechanisms associated with new drugs against Enterobacterales.</p><p><strong>Sources: </strong>We searched PubMed relevant English literature in up to 30 June 2025, as well as including articles known to the authors. We analysed Enterobacterales resistance mechanisms for diazabicyclooctanes, bicyclic boronates, cefepime/enmetazobactam, cefiderocol, and eravacycline.</p><p><strong>Content: </strong>The review summarises the main mechanisms of resistance to recently introduced ß-lactamase inhibitor families, including diazabicyclooctanes and bicyclic boronates, as well as other novel combinations or antimicrobials, such as cefiderocol and eravacycline.</p><p><strong>Implications: </strong>Understanding how microorganisms develop resistance to new antimicrobials or combinations with inhibitors is essential for redesigning treatment strategies and for the design of future antibiotics.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From rigid to rapid: rethinking clinical trial processes for emergency-ready clinical trials. 从严格到快速:重新思考应急临床试验的临床试验过程。
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-07 DOI: 10.1016/j.cmi.2025.12.028
Denise van Hout, Cristina Prat-Aymerich, Karen van Hulst, Jeri Nijland, Oliver A Cornely, Patricia Bruijning-Verhagen
{"title":"From rigid to rapid: rethinking clinical trial processes for emergency-ready clinical trials.","authors":"Denise van Hout, Cristina Prat-Aymerich, Karen van Hulst, Jeri Nijland, Oliver A Cornely, Patricia Bruijning-Verhagen","doi":"10.1016/j.cmi.2025.12.028","DOIUrl":"10.1016/j.cmi.2025.12.028","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.5,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 374-381"},"PeriodicalIF":8.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146216287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 1","pages":"Pages 80-86"},"PeriodicalIF":8.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146237773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 1","pages":"Pages 62-69"},"PeriodicalIF":8.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146237776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 8.5 1区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2026-01-01
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 1","pages":"Pages 41-55"},"PeriodicalIF":8.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146237781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Microbiology and Infection
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1